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cense.Abstract Background and purpose: Ampliﬁcation of Her-2/neu gene occurs in 25–30% of breast
carcinomas. FDA approved trastuzumab (Herceptin) is effective only in tumors having the gene
ampliﬁcation. Immunohistochemistry (IHC) for Her-2/neu protein is widely used but false positive
and false negative results exist. Fluorescence in-situ hybridization (FISH) has both excellent sensi-
tivity and speciﬁcity in detecting Her-2/neu ampliﬁcation. Comparative studies have shown discor-
dant results in proportion of cases with equivocal 2+ immunostain. This study is thus conducted to
ascertain the frequency of Her-2/neu gene ampliﬁcation by FISH in breast carcinoma speciﬁed as
score 2+ by IHC and to correlate these ﬁndings with parameters of prognosis in breast cancer.
Methods: From October 2008 till May 2010 all parafﬁn blocks from cases with invasive breast car-
cinoma which were scored as 2+ by IHC were eligible for the study, there were 50 cases. Immuno-
histochemical evaluation of Her-2/neu was performed using the HercepTest. All cases were
immunohistochemically evaluated for ER and PR. FISH was performed using FDA approved
Path-Vysion Her-2/neu/CEP 17 dual color probe.
Results: Nine cases (18%) out of 50 cases scored as Her-2/neu 2+ by IHC showed true gene ampli-
ﬁcation with a median value of scoring ratio 4.28 ranging from 2.37 to 13.26. Another two cases664452.
.cm (N.A.E. Mostafa).
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42 N.A.E. Mostafa et al.showed low level of ampliﬁcation but when corrected for Her-2/neu/CEP ratio they did not show
true ampliﬁcation as they were associated with polysomy 17. With the exception of tumor size, nei-
ther patient’s age, histologic grade nor lymph node status were correlated with Her-2/neu gene
ampliﬁcation. Signiﬁcant inverse correlation existed between Her-2/neu gene ampliﬁcation and
ER (P= 0.01), PR status (P< 0.001).
Conclusion: Even though FISH is a more complex and expensive procedure, it should be consid-
ered the method of choice for assessment of Her-2/neu gene status especially for equivocal cases
by IHC that are not accompanied by true gene ampliﬁcation in the majority of breast carcinoma
cases.
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of breast carcinoma (200·).Introduction
Her-2/neu (erbB2) proto-oncogene encodes a type I tyrosine
kinase receptor that is homologous to the epidermal growth
factor receptor and is located on the long arm of chromosome
17. Her-2 induces cell division and stimulates factors facilitat-
ing cell motility [1,2].
With the exception of small fraction of cases, overexpres-
sion of the protein product of Her-2/neu gene is usually a
direct consequence of gene ampliﬁcation. Ampliﬁcation of
Her-2/neu gene occurs in 25–30% of breast carcinomas and re-
sults in over expression of gene product [3,4]. Gene ampliﬁca-
tion of Her-2/neu oncogene is associated with rapid tumor
growth, increased risk of recurrence after surgery, poor re-
sponse to conventional chemotherapy and it predicts worse
prognosis with signiﬁcantly decreased disease free survival
and overall survival [5,6].
Testing to determine Her-2/neu status has come into focus
since the approval of trastuzumab for the treatment of Her-2
positive breast cancer. FDA approved trastuzumab (Hercep-
tin) binds to the extracellular domain of Her-2/neu and blocks
cell proliferation of tumor cells that overexpress Her-2/neu. It
also induces antibody dependant cellular toxicity against tu-
mor cells [7]. Lapatinib, Her-1/Her-2 dual receptor inhibitor
is also being introduced as an effective modality treatment
for patients expressing gene ampliﬁcation. Unfortunately, the
treatment is expensive and carries serious adverse effects like
cardiotoxicity with Herceptin. Both drugs being effective only
in tumors having the gene ampliﬁcation [3,8].
Accurate assessment of erbB2 status in individual tumor
cells is mandatory before application of speciﬁc therapy strat-
egies and has thus taken on great importance in routine work
up of breast cancer, complementing the prognostic and predic-
tive markers used [9–11].
Various techniques are available for assessment of Her-2/
neu status in tumor cells. These include detection of gene
ampliﬁcation (Southern blot, PCR, ﬂuorescent in situ hybrid-
ization; [FISH], messenger RNA [Northern blot, RT-PCR] or
amount of protein [Western blot, ELISA, immunohistochem-
istry; IHC]) [5,12].
Currently the two most widely used technologies for assess-
ment of Her-2/neu are IHC and FISH, both of which can be
applied on formalin ﬁxed parafﬁn embedded tissues. FISH
has both excellent sensitivity and speciﬁcity in detecting Her-
2 ampliﬁcation but with high requisite of special instrumenta-
tion and expertise to perform and interpret the assay [3,13].
IHC for Her-2/neu protein is widely used but false positive
and false negative results are present. Comparative studieshave shown high concordance rates between IHC analysis
and FISH in cases with IHC scores 0, 1+ and 3+. However,
discordant results are signiﬁcant in proportion of cases with
equivocal 2+ immunostain [9,14,15].
This study is thus conducted to ascertain the frequency of
Her-2/neu gene ampliﬁcation in breast carcinoma speciﬁed as
score 2+ by IHC and to associate these ﬁndings with clinico-
pathologic parameters (age, tumor size, lymph node metasta-
sis,), in addition to estrogen receptor (ER) and progesterone
receptor (PR) states.
Materials and methods
From October 2008 till May 2010 all Parafﬁn blocks from
cases with invasive breast carcinoma, which were scored as
2+ by IHC were eligible for the study (50 cases). The tumor
specimens of blocks were previously ﬁxed in neutral buffered
formalin and embedded in parafﬁn. Blocks from patients with
metastatic or recurrent breast cancer were eligible for FISH
study if they were scored as 2+ by IHC. Patients with pure
duct carcinoma in situ (DCIS) were excluded from the study.
Clinical and demographic data including patient’s age, tumor
size, and lymph node status were recorded for each case.
Immunohistochemical evaluation of Her-2/neu was per-
formed using the HercepTest (Dako, Glostrup, Denmark)
according to the manufacturer’s instructions. The assessment
of Her-2/neu overexpression was performed as recommended
by the following HercepTest scoring guidelines: 0; no staining
or less than 10% membrane staining, 1+; partial membrane
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moderate complete membrane staining in greater than 10% of
the tumor cells (Fig. 1), 3+; strong completemembrane staining
in greater than 10% of the tumor cells (HercepTest guidelines).
All cases were immunohistochemically evaluated for hor-
mone receptor state (ER and PR) according to Allred score
[16]. In brief, a total scoring of proportion scoring (PS) and
intensity scoring (IS) was done with 0–2 considered negative
and 3–8 considered positive.
Fluorescence in-situ hybridization (FISH) was performed
using FDA approved Path-Vysion Her-2/neu DNA probe kit
(Abott, Molecular Inc., IL, USA) which contained two labeled
DNA probes: the Her-2/neu probe which comprises locus spe-
ciﬁc identiﬁer (LSI) Her-2/neu gene labeled in spectrum or-
ange, and chromosome enumeration probe 17 (CEP 17)
which is labeled in spectrum green and hybridizes to the alpha
satellite DNA located at the centromere of chromosome 17
(17p11.1). Inclusion of CEP 17 relative to the copy number
of chromosome 17 allows the copy number of the Her-2/neu
gene to be determined.
Tissue sections prepared from corresponding parafﬁn
blocks were mounted on poly-L-lysine coated glass slides.
Slides were air dried and baked overnight at 56 C, dewaxed
in xylene followed by immersion in 100% ethanol for 2 min.
Pretreatment of the sections for 10 min at 70 C, followed by
pepsin digestion at 37 C for 15 min was done. Before denatur-
ation, slides were warmed at 60 C and an appropriate amount
of hybridization mixture was applied onto the tissue sections
according to the size. Co-denaturation and hybridization were
simultaneously done using Tissue Hybite (Vysis).
Slides were then washed with 0.4% SSC wash buffer, and
counterstained with DAPI. Scoring was done using Zeiss axi-Table 1 Correlation of Her-2 status with clinical, histopathologic a
Parameter Number Her-2/neu by FI
Non-ampliﬁed (n
n %
Age (years)
635 13 11 (84.6)
>35 37 30 (81.1)
Median 43
Range 25–72
Tumor size (cm)
Mean, SD 3.2, 1.7
Histologic grade
GII 38 33 (86.8)
GIII 12 8 (66.7)
Lymph nodes
Negative 7 7 (100.0)
Positive 43 34 (79.0)
Number of LNs
N 6 3 18 16 (88.9)
N> 3 25 18 (72.0)
ER
Negative 8 2
Positive 42 39
PR
Negative 12 6 (50.0)
Positive 38 35 (92.1)oscope ﬂuorescent microscope (Zeiss Ltd., Germany) equipped
with specially designed excitation and emission ﬁlter sets, dual
band and triple bandpass ﬁlters, and cooled CCD camera. For
each case the following factors were noted: adequacy of diges-
tion, intensity of ﬂuorescent signals, nonspeciﬁc ﬂuorescent
background, tissue histology, and areas with non-overlapping
nuclei. Thirty randomly selected invasive nuclei in each of the
two separately distinct microscopic areas were evaluated (a to-
tal of 60 per case). Results on the enumeration of 60 interphase
nuclei from tumor cells per target were reported as the ratio of
the average Her-2/neu copy number (orange) relative to that of
CEP 17 (green). Other features like polysomy 17 were noted.
The interpretation of the FISH assay was done following
the ASCO/College of American Pathologists (CAP) guidelines.
A ratio of HER-2/neu to CEP 17 signals higher than 2.2 was
reported as ampliﬁcation, a ratio less than 1.8 was reported
as non-ampliﬁcation, while a ratio between 1.8 and 2.2 was ta-
ken as an equivocal result. A recounting of additional 20 tu-
mor nuclei (i.e. total 80) was done for the equivocal cases.
The assay was repeated in case of failure due to technical prob-
lems like excess parafﬁn in the tissue, excess background auto-
ﬂuorescence, no gene signal or improper protease digestion.
Normal and ampliﬁed control slides, Probe Check, were run
simultaneously with the test cases. The slides were then stored
in the dark at 20 C. Cases were scored independently by two
observers.
Statistical evaluation
Statistical package for social science (SPSS) version 12 was
used for data management and analysis. To test the differ-
ence between groups with respect to quantitative variables,nd ER, PR status.
SH P-value
= 41) Ampliﬁed (n= 9)
n %
2 (13.4) 0.775
7 (28.9)
43
28–55
4.7, 2 0.030
5 (13.2) 0.113
4 (33.3)
0 (0.0) 0.181
9 (21.0)
2(11.1) 0.138
7 (28.0)
6 <0.001
3
6 (50.0) 0.010
3 (7.9)
Figure 3 FISH of Her-2/neu on parafﬁn embedded tissue
sections in a case of breast carcinoma, tumor cells with ampliﬁed
Her-2/neu (orange signals) and increased centromeric chromo-
some 17 signals (green signals); non-ampliﬁed. (Oil immersion
1000·.)
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square test and ﬁsher exact were used. Spearman correlation
coefﬁcient was calculated to test the association between nu-
meric and ordinal variables. Signiﬁcant level was 60.05.
Results
Clinical and histopathologic parameters
All patients were females with mean age of 43.9 years and a
standard deviation of ±11.3 years. The age range was from
28 to 72 years. Twenty-six patients were 635 years, while
74% were >35 years of age. Forty-eight cases (96%) were
invasive duct carcinoma while 2 cases were invasive lobular
carcinoma. As regards tumor size, 11 cases (22%) were T1
(<2 cm); 31 cases (62%) were T2 (2–5 cm); while 8 cases
(16%) were T3 (>5 cm). Twelve cases (24%) were grade 3
while the remaining 76% were all grade 2. Four cases showed
extensive intra-duct component in the form of comedo, solid
and cribriform patterns while lymphovascular invasion was de-
tected in three cases. Lymph node metastasis was present in 43
cases (86%), N0 cases represented 14% of the cases, N1 (1–3
LNs) was reported in 18 cases, N2 (4–10 LNs) 16 cases, while
N3 (>10 LNs) was documented in 9 cases. Capsular nodal
invasion was present in about 6 cases.
Immunohistochemical ER and PR evaluation
Eight cases were ER negative and 12 cases were PR negative.
Seven cases showed both ER and PR negative cases. As re-
gards the relation between ER and PR it was highly signiﬁcant
since 7 cases were both ER and PR negative and 37 cases were
both ER and PR positive, P value <0.001 (Table 1).
FISH interpretation
Out of 50 cases scored as Her-2/neu 2+ by IHC and investi-
gated for FISH, 9 cases (18%) showed true gene ampliﬁcationFigure 2 FISH of Her-2/neu on parafﬁn embedded tissue
sections in a case of breast carcinoma. Tumor cells show no
ampliﬁcation of Her-2/neu. Presence of an average of two orange
signals and two green signals/cell. (Oil immersion 1000·.)(Figs. 4 and 5) with a median value of Her-2/CEP 17 ratio of
4.28 ranging from 2.37 to 13.26.
Another two cases showed low level of ampliﬁcation but
when corrected for Her-2/neu/CEP ratio they did not show
true ampliﬁcation as they were associated with polysomy 17
(Fig. 3). Polysomy 17 thus accounts for about 4% of our cases.
Thirty-nine cases showed no ampliﬁcation (Fig. 2).
One case showed expression of ER, PR and Her-2/neu gene
ampliﬁcation (triple positive). The case was grade 3, tumor
size >2 cm and with >10 positive nodes. Two cases showed
neither expression of ER, PR nor Her-2 neu gene (triple
negative).Figure 4 FISH of Her-2/neu probe on parafﬁn embedded tissue
sections in a case of breast carcinoma showing tumor cells with
high level of ampliﬁed Her-2/neu. Presence of numerous orange
signals arranged in clusters. (Oil immersion 1000·.)
Figure 5 FISH of Her-2/neu probe on parafﬁn embedded tissue
sections in another case of breast carcinoma showing tumor cells
with high level of ampliﬁed Her-2/neu. Presence of numerous
orange signals, some are arranged in clusters. (Oil immersion
1000·.)
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hormonal state
The tumor size showed signiﬁcant association with ampliﬁed
Her-2/neu gene (p value 0.03) with a mean size of 4.7 cm
among ampliﬁed cases compared to 3.2 cm among non-ampli-
ﬁed cases. Two out of 18 cases (11.1%) with LN 6 3 showed
ampliﬁed Her-2/neu compared to 7 cases (28%) out of 25 with
LN> 3 showing ampliﬁed Her-2/neu (P= 0.138) (Table 1).
Seventy-ﬁve percent (75%) of ER negative cases were
ampliﬁed compared to 7.1% among ER positive cases with
P< 0.001. On the other hand 50% of PR negative cases were
ampliﬁed compared to 7.9% among PR positive cases with a
statistically signiﬁcant difference, P= 0.001. No signiﬁcant
relation was found between tumor grade and Her-2/neu ampli-
ﬁcation (P= 0.113). There was good positive correlation be-
tween tumor size and lymph node positivity (r= 0.57,
P< 0.001) (Table 1).
Discussion
Evaluation of Her-2/neu gene status has become part of the
core dataset in pathologic reporting of invasive breast cancer
[3,10]. Despite some evidence that FISH testing predicts the
therapeutically signiﬁcant Her-2/neu status more accurately,
the approach of primary immunohistochemistry screening
with supplementary FISH molecular conﬁrmation is widely
used. Nevertheless, many centers recommend the initial assess-
ment of cases of invasive breast cancer by IHC supplemented
by FISH when IHC results are equivocal [17–19]. Several stud-
ies showed that score 2+ Her-2/neu by IHC is infrequently
accompanied by true gene ampliﬁcation [2,7,9], while others
reported signiﬁcant higher rates [8,15].
In this study, the percentage of cases assigned as Her-2/neu
score 2+ by IHC that showed true gene ampliﬁcation was
about 18%. This is comparable to previous studies that
showed ampliﬁcation range from 6% to 25% of IHC 2+/
FISH ampliﬁed cases [9,19]. ASCO/CAP guidelines reportedan incidence of 23.9% [20]. Such cases with score 2+ by
IHC and with negative gene ampliﬁcation are considered false
positive by IHC. Possible explanations for these results could
be attributed to variation in time ﬁxation, processing condi-
tions that can lead to variation in the intensity of staining espe-
cially with the use of heat inactivation epitope retrieval that
can cause false positive results [18,21,22]. Tumor heterogeneity
is another possible explanation which is documented in many
tumors with the presence of a clone that is biologically differ-
ent from nearby clones [23,24].
One case showed expression of ER, PR and Her-2/neu (tri-
ple positive). Her-2/neu ampliﬁcation is reported to be associ-
ated with resistance to tamoxifen therapy. It is postulated that
in these cases tamoxifen functions as an estrogen agonist to
stimulate growth in breast cancer cells, which express an in-
creased level of Her-2 and ER co activation resulting in deno-
vo resistance for tamoxifen [25,26]. Two cases in this study
showed triple negative results (ER, PR, Her-2/neu). Triple neg-
ative cases, which probably represent a speciﬁc type of breast
cancer known as basal type, are also known to be resistant
to tamoxifen with rapidly progressive clinical course [27,28].
Two of the cases in this study showed polysomy 17. The fre-
quency of polysomy 17 varies from 10% to 50%. ASCO re-
ported that 8% of equivocal cases exhibit polysomy 17.
Several studies have conﬁrmed that protein overexpression
may be secondary to polysomy 17 with resultant increase in
the copies of Her-2/neu gene in the absence of gene ampliﬁca-
tion. These are almost considered Her-2/neu negative tumors
rather than tumors with true Her-2/neu gene ampliﬁcation
[29].
As regards clinicopathologic correlation, no statistically
signiﬁcant association existed between Her-2/neu gene ampliﬁ-
cation and age, grade or lymph nodes metastasis. This was also
reported by other investigators [5,7]. Tumor size showed signif-
icant association with Her-2/neu gene ampliﬁcation in concor-
dance with other studies [14]. Many investigators found
signiﬁcant association with ER, PR hormone status and is con-
sidered an important guide for therapy [4,6–8]. Similar ﬁndings
were reported in our study.
Even though FISH is a more complex and expensive pro-
cedure, it should be considered the method of choice for
assessment of Her-2/neu gene status especially for equivocal
cases by IHC that are not accompanied by true gene ampliﬁ-
cation in the majority of breast carcinoma cases. False treat-
ment with trastuzumab in the positive cases by IHC not
only leads to loss of money of the patient or the government
but also it means psychological burden to the patient who was
waiting for improvement with the expensive drug, this is
added to the exposure to side effects of the drug without
any beneﬁt. So, although FISH is expensive, it is more cost
effective in cases of score 2+ immunostaining. This is because
the price of trastuzumab is much higher than the cost of per-
forming FISH, in addition to the psychological burden of
false treatment and side effects of the drug. Failure to detect
FISH ampliﬁed cases would have an adverse effect on survival
of these patients. FISH also has the great advantage of eval-
uation of chromosome 17 status at the same setting for correc-
tion of ampliﬁed cases due to chromosome 17 polysomy. On
the other hand, IHC expression without gene ampliﬁcation
appears to belong to a better prognostic group; failure to de-
tect this group would have negative effect on survival of these
patients.
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